PD09: Bladder Cancer: Invasive I

Podium Session Moderator(s)

• 

  Nima Almassi, MD (he/him/his)

  Urologic Oncologist
  Cleveland Clinic
• 

  Mario Alvarez-Maestro, Sr, MD
• 

  Michael Cookson, MD (he/him/his)

  Professor and Chair
  University of Oklahoma

Presentations:

• 1:00 PM – 1:10 PM CST

  PD09-01: The Tolerability and Efficacy of BCG Administration after Recurrence in Bladder-preserving Therapy For Muscle-invasive Bladder Cancer
  

  Podium Presenter: Ruiyang Xie, MD (he/him/his) – Peking University Third Hospital
• 1:10 PM – 1:20 PM CST

  PD09-02: THE IMPACT OF VARIANT HISTOLOGY ON CLINICAL OUTCOMES AFTER RADIATION-BASED THERAPY FOR MUSCLE-INVASIVE BLADDER CANCER
  

  Podium Presenter: Daniel Halstuch, MD – Yale New Haven Health
• 1:20 PM – 1:30 PM CST

  PD09-03: Inverse Probability Treatment Weighting comparison of radical cystectomy to trimodality therapy for cT2-cT4 muscle invasive bladder cancer
  

  Podium Presenter: Jason Efstathiou, MD (he/him/his) – Mass General Brigham/Massachusetts General Hospital, Harvard Medical School
• 1:30 PM – 1:40 PM CST

  PD09-04: Prediction of 90-day mortality after radical cystectomy for bladder cancer in large-scale multicenter collaboration study
  

  Podium Presenter: Ekaterina Laukhtina, MD – Medical University of Vienna
• 1:40 PM – 1:50 PM CST

  PD09-05: Standard Versus Extended Lymph Node Dissection at the Time of Radical Cystectomy for Bladder Cancer
  

  Podium Presenter: Alejandro Abello, MD
• 1:50 PM – 2:00 PM CST

  PD09-06: 15-Year Outcomes of Robot-Assisted Radical Cystectomy: Results from the International Radical Cystectomy Consortium
  

  Podium Presenter: Jorge A. Daza, MD (he/him/his)
• 2:00 PM – 2:10 PM CST

  PD09-07: Assessing the utility of a cell-free tumor (ct)DNA assay (MSK-ACCESS) in node positive (N+) muscle invasive bladder cancer (MIBC) patients (pts) undergoing neoadjuvant chemotherapy (NAC)
  

  Podium Presenter: Andrew B. Katims, MD – Memorial Sloan Kettering Cancer Center
• 2:10 PM – 2:20 PM CST

  PD09-08: Impact of neoadjuvant chemotherapy-induced acute kidney injury on oncological outcomes in patients who underwent radical cystectomy: A multicenter retrospective study
  

  Podium Presenter: Naoki Fujita, MD
• 2:20 PM – 2:30 PM CST

  PD09-09: Survival Benefits of Adjuvant Chemotherapy for Positive Soft Tissue Surgical Margins Following Radical Cystectomy in Bladder Cancer with Extravesical Extension
  

  Podium Presenter: Prithvi Murthy, MD – Moffitt Cancer Center
• 2:30 PM – 2:40 PM CST

  PD09-10: Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): long-term outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1L chemotherapy
  

  Podium Presenter: Shilpa Gupta, MD – Cleveland Clinic Foundation
• 2:40 PM – 2:50 PM CST

  PD09-11: The immune-related adverse events paradox in locally advanced or metastatic urothelial cancer patients receiving atezolizumab: Analysis of individual participant data from IMvigor210 and IMvigor211
  

  Podium Presenter: Daniele Robesti, MD – Universtià Vita Salute San Raffaele
• 2:50 PM – 3:00 PM CST

  PD09-12: The Use of ⁶⁸Ga-FAP-2286 PET Imaging in Patients with Localized Bladder Cancer
  

  Podium Presenter: Domenique Escobar, MD